| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Former Chief Financial Officer | VP, Chief Financial Officer
1 company
Ryan Dunlap is Former Chief Financial Officer at SLS. Ryan Dunlap's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $166K at current prices.
The SLS filings lean toward selling, a net 126,875 shares.
Ryan Dunlap has 6 Form 4 filings on record from January 2015 to March 2026, across 2 companies: Director at CytoDyn (CYDY), 2022–2026; Former Chief Financial Officer at SELLAS Life Sciences Group (SLS), 2015–2016.
The 10 reported transactions were 5 option or other derivative awards, 3 option exercises, 1 open-market sale and 1 other transaction.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $277K.
The only open-market sale was 126,875 shares of SLS at an average $2.18 on June 1, 2016, about $277K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2016 | SLS Sellas Life Sciences Group, Inc. | Former Chief Financial Officer | Sale+OE | 126,875 | $2.18 | $276,587.50 | -87.2% |